ESR1 and breast cancer: It is apparent that future studies are necessary to determine the intricate mechanisms underlying tamoxifen resistance, and to elucidate the cause of events rendering CCND1 amplified premenopausal breast cancers not only resistant but possibly stimulated by this selective ER modulator.